Boehringer-Ingelheim Pharmaceuticals Inc. | USA

James Smith completed his bachelor’s degree in biochemistry and cell biology at the University of Cape Town in South Africa; where he also completed his graduate studies in the department of Cardio-Thoracic surgery. Following this, James worked as a research associate at Yale University-Howard Hughes Medical Institute in the laboratory of Dr Sandra Wolin, contributing to the understanding of the role of small non-coding RNAs in autoimmune disease. In 2008, he took on his first Industry position in the Cardiometabolic Disease Drug Discovery group at Boehringer-Ingelheim Pharmaceuticals Inc. James joined the Non-clinical Drug Safety department in 2010 and is the biomarker representative for Development US; responsible for pharmacodynamic and safety biomarker strategy.